Notice of General Meeting - Correction

RNS Number : 2578Y

e-Therapeutics plc

13 May 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Notice of General Meeting - Correction

On 11 May 2016 the Company announced the proposed acquisition of Searchbolt Limited (the "Acquisition") together with a notice of general meeting to approve the Acquisition (the "General Meeting") (the "Announcement"). The location of the General Meeting was incorrectly stated in the Announcement.

The General Meeting is being held at 12.00 noon on 27 May 2016 at the Company's registered office, 17 Blenheim Office Park, Long Hanborough, Oxon, OX29 8LN, and not at the offices of Bond Dickinson LLP, 4 More London Riverside, London, SE1 2AU as was incorrectly stated in the Announcement.

All other details in the Announcement remain unchanged.

-Ends-

Contacts:

e-Therapeutics plc Malcolm Young, CEO Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell / Jayne Crook / Emma Barlow	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery. 

e-Therapeutics has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.  

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk.  

 

END

 

 

NOGBUGDUUGBBGLX